In this webinar, Dr. Magali Cordaillat-Simmons, Scientific and Regulatory Affairs Director at the PRI will address the importance of considering the regulatory status of a future microbiome-based product at every stage of the development including the early developments carried out in the academia.
Indeed, regulatory aspects are often considered as only relevant for the industry but for microbiome-derived drug products, as well as any other pharmaceuticals, the constrains associated with a pharma development should be taken into account as early as the proof of concept studies.
Throughout the session, Dr. Cordaillat-Simmons will discuss:
Duration: 30 minutes
Date: Wednesday May 16, 2018
Time: 12:00pm – 12:30pm Eastern Time/ 18:00pm – 18:30pm Central European Time
Registration link: https://attendee.gotowebinar.com/register/297546928529215234
Name: Magali Cordaillat-Simmons
Job Title: Scientific and Regulatory Affairs Director
Company Name: PRI